Association between GSTP1 Ile105Val polymorphism and oxaliplatin-induced neuropathy: A systematic review and meta-analysis

Cancer Chemotherapy and Pharmacology

Volumn 72, Issue 2, 2013, Pages 305-314

  Peng, Zhi ^a,c   Wang, Qianqian ^b   Gao, Jing ^a   Ji, Zhaoning ^c   Yuan, Jiajia ^a   Tian, Ye ^a   Shen, Lin ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^b Beijing Institute of Traumatology and Orthopaedics   (China)

^c WANNAN MEDICAL COLLEGE   (China)

Author keywords

GSTP1; Meta analysis; Neuropathy; Polymorphism

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; ISOLEUCINE; OXALIPLATIN; RALTITREXED; VALINE;

ADULT; ADVANCED CANCER; AGED; ALLELE; AMINO ACID SUBSTITUTION; CANCER CHEMOTHERAPY; COLORECTAL CANCER; DATA ANALYSIS; DIGESTIVE SYSTEM CANCER; DISEASE ASSOCIATION; FEMALE; GENE; GENETIC CORRELATION; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GSTP1 GENE; HUMAN; MALE; META ANALYSIS; NEUROPATHY; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; STOMACH CANCER; SYSTEMATIC REVIEW;

ALLELES; ANTINEOPLASTIC AGENTS; CONFIDENCE INTERVALS; GENOTYPE; GLUTATHIONE S-TRANSFERASE PI; HUMANS; KIDNEY DISEASES; NEOPLASMS; ORGANOPLATINUM COMPOUNDS; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; PUBLICATION BIAS; RETROSPECTIVE STUDIES;

EID: 84880921690     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2194-x     Document Type: Review

References (44)

1. Raymond E, Chaney SG, Taamma A, Cvitkovic E (1998) Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 9(10):1053-1071 (Pubitemid 28518143)
2. Stein A, Arnold D (2012) Oxaliplatin: a review of approved uses. Expert Opin Pharmacother 13(1):125-137
3. Price TJ, Shapiro JD, Segelov E, Karapetis CS, Pavlakis N, Van Cutsem E, Shah MA, Kang YK, Tebbutt NC (2011) Management of advanced gastric cancer. Expert Rev Gastroenterol Hepatol 6(2):199-208 (quiz 209)
4. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardiere C, Bennouna J, Bachet JB, Khemissa-Akouz F, Pere-Verge D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364(19):1817-1825
5. Mir O, Boudou-Rouquette P, Giroux J, Chapron J, Alexandre J, Gibault L, Ropert S, Coriat R, Durand JP, Burgel PR, Dusser D, Goldwasser F (2012) Pemetrexed, oxaliplatin and bevacizumab as first-line treatment in patients with stage IV non-small cell lung cancer. Lung Cancer 77(1):104-109
6. Weickhardt A, Wells K, Messersmith W (2011) Oxaliplatin-induced neuropathy in colorectal cancer. J Oncol 2011:201593
7. Durand JP, Deplanque G, Montheil V, Gornet JM, Scotte F, Mir O, Cessot A, Coriat R, Raymond E, Mitry E, Herait P, Yataghene Y, Goldwasser F (2012) Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial. Ann Oncol 23(1):200-205
8. Hoff PM, Saad ED, Costa F, Coutinho AK, Caponero R, Prolla G, Gansl RC (2012) Literature review and practical aspects on the management of oxaliplatin-associated toxicity. Clin Colorectal Cancer 11(2):93-100
9. Grothey A (2005) Clinical management of oxaliplatin-associated neurotoxicity. Clin Colorectal Cancer 5(Suppl 1):S38-S46
10. Cavaletti G, Alberti P, Marmiroli P (2011) Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics. Lancet Oncol 12(12):1151-1161
11. Inada M, Sato M, Morita S, Kitagawa K, Kawada K, Mitsuma A, Sawaki M, Fujita K, Ando Y (2010) Associations between oxaliplatin-induced peripheral neuropathy and polymorphisms of the ERCC1 and GSTP1 genes. Int J Clin Pharmacol Ther 48(11):729-734
12. Lecomte T, Landi B, Beaune P, Laurent-Puig P, Loriot MA (2006) Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clin Cancer Res 12(10):3050-3056 (Pubitemid 43837350)
13. Gamelin L, Capitain O, Morel A, Dumont A, Traore S, le Anne B, Gilles S, Boisdron-Celle M, Gamelin E (2007) Predictive factors of oxaliplatin neurotoxicity: the involvement of the oxalate outcome pathway. Clin Cancer Res 13(21):6359-6368 (Pubitemid 350075025)
14. Argyriou AA, Antonacopoulou AG, Scopa CD, Kottorou A, Kominea A, Peroukides S, Kalofonos HP (2009) Liability of the voltage-gated sodium channel gene SCN2A R19K polymorphism to oxaliplatin-induced peripheral neuropathy. Oncology 77(3-4):254-256
15. Antonacopoulou AG, Argyriou AA, Scopa CD, Kottorou A, Kominea A, Peroukides S, Kalofonos HP (2010) Integrin beta-3 L33P: a new insight into the pathogenesis of chronic oxaliplatin-induced peripheral neuropathy? Eur J Neurol 17(7):963-968
16. Basso M, Modoni A, Spada D, Cassano A, Schinzari G, Lo Monaco M, Quaranta D, Tonali PA, Barone C (2011) Polymorphism of CAG motif of SK3 gene is associated with acute oxaliplatin neurotoxicity. Cancer Chemother Pharmacol 67(5):1179-1187
17. Cecchin E, D'Andrea M, Lonardi S, Zanusso C, Pella N, Errante D, De Mattia E, Polesel J, Innocenti F, Toffoli G (2012) A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen. Pharmacogenomics J [Epub ahead of print]
18. Hayes JD, Flanagan JU, Jowsey IR (2005) Glutathione transferases. Annu Rev Pharmacol Toxicol 45:51-88 (Pubitemid 40261798)
19. Di Pietro G, Magno LA, Rios-Santos F (2010) Glutathione S-transferases: an overview in cancer research. Expert Opin Drug Metab Toxicol 6(2):153-170
20. McIlwain CC, Townsend DM, Tew KD (2006) Glutathione S-transferase polymorphisms: cancer incidence and therapy. Oncogene 25(11):1639-1648
21. Vasieva O (2011) The many faces of glutathione transferase pi. Curr Mol Med 11(2):129-139
22. Watson MA, Stewart RK, Smith GB, Massey TE, Bell DA (1998) Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis 19(2):275-280 (Pubitemid 28375421)
23. Ishimoto TM, Ali-Osman F (2002) Allelic variants of the human glutathione S-transferase P1 gene confer differential cytoprotection against anticancer agents in Escherichia coli. Pharmacogenetics 12(7):543-553 (Pubitemid 35177084)
24. Li QF, Yao RY, Liu KW, Lv HY, Jiang T, Liang J (2010) Genetic polymorphism of GSTP1: prediction of clinical outcome to oxaliplatin/5-FU-based chemotherapy in advanced gastric cancer. J Korean Med Sci 25(6):846-852
25. Chen YC, Tzeng CH, Chen PM, Lin JK, Lin TC, Chen WS, Jiang JK, Wang HS, Wang WS (2009) Influence of GSTP1 I105V polymorphism on cumulative neuropathy and outcome of FOLFOX-4 treatment in Asian patients with colorectal carcinoma. Cancer Sci 101(2):530-535
26. Pare L, Marcuello E, Altes A, del Rio E, Sedano L, Salazar J, Cortes A, Barnadas A, Baiget M (2008) Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy. Br J Cancer 99(7):1050-1055
27. Hong J, Han SW, Ham HS, Kim TY, Choi IS, Kim BS, Oh DY, Im SA, Kang GH, Bang YJ, Kim TY (2011) Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis. Cancer Chemother Pharmacol 67(6):1323-1331
28. McLeod HL, Sargent DJ, Marsh S, Green EM, King CR, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Thibodeau SN, Grothey A, Morton RF, Goldberg RM (2010) Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. J Clin Oncol 28(20):3227-3233
29. Kanai M, Yoshioka A, Tanaka S, Nagayama S, Matsumoto S, Nishimura T, Niimi M, Teramukai S, Takahashi R, Mori Y, Kitano T, Ishiguro H, Yanagihara K, Chiba T, Fukushima M, Matsuda F (2010) Associations between glutathione S-transferase pi Ile105Val and glyoxylate aminotransferase Pro11Leu and Ile340Met polymorphisms and early-onset oxaliplatin-induced neuropathy. Cancer Epidemiol 34(2):189-193
30. Kweekel DM, Gelderblom H, Antonini NF, Van der Straaten T, Nortier JW, Punt CJ, Guchelaar HJ (2009) Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients. Eur J Cancer 45(4):572-578
31. Goekkurt E, Al-Batran SE, Hartmann JT, Mogck U, Schuch G, Kramer M, Jaeger E, Bokemeyer C, Ehninger G, Stoehlmacher J (2009) Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie. J Clin Oncol 27(17):2863-2873
32. Boige V, Mendiboure J, Pignon JP, Loriot MA, Castaing M, Barrois M, Malka D, Tregouet DA, Bouche O, Le Corre D, Miran I, Mulot C, Ducreux M, Beaune P, Laurent-Puig P (2010) Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. J Clin Oncol 28(15):2556-2564
33. Ruzzo A, Graziano F, Loupakis F, Rulli E, Canestrari E, Santini D, Catalano V, Ficarelli R, Maltese P, Bisonni R, Masi G, Schiavon G, Giordani P, Giustini L, Falcone A, Tonini G, Silva R, Mattioli R, Floriani I, Magnani M (2007) Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol 25(10):1247-1254 (Pubitemid 46640571)
34. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177-188 (Pubitemid 17189972)
35. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557-560 (Pubitemid 37088507)
36. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629-634 (Pubitemid 27387172)
37. Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25(9):603-605
38. Townsend DM, Tew KD (2003) The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene 22(47):7369-7375
39. Goto S, Iida T, Cho S, Oka M, Kohno S, Kondo T (1999) Overexpression of glutathione S-transferase pi enhances the adduct formation of cisplatin with glutathione in human cancer cells. Free Radic Res 31(6):549-558
40. Zhong SL, Zhou SF, Chen X, Chan SY, Chan E, Ng KY, Duan W, Huang M (2006) Relationship between genotype and enzyme activity of glutathione S-transferases M1 and P1 in Chinese. Eur J Pharm Sci 28(1-2):77-85
41. Holley SL, Fryer AA, Haycock JW, Grubb SE, Strange RC, Hoban PR (2007) Differential effects of glutathione S-transferase pi (GSTP1) haplotypes on cell proliferation and apoptosis. Carcinogenesis 28(11):2268-2273 (Pubitemid 350111584)
42. Mir O, Alexandre J, Tran A, Durand JP, Pons G, Treluyer JM, Goldwasser F (2009) Relationship between GSTP1 Ile(105)Val polymorphism and docetaxel-induced peripheral neuropathy: clinical evidence of a role of oxidative stress in taxane toxicity. Ann Oncol 20(4):736-740
43. Zintzaras E, Ioannidis JP (2005) Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol 28(2):123-137
44. Saif MW, Reardon J (2005) Management of oxaliplatin-induced peripheral neuropathy. Ther Clin Risk Manag 1(4):249-258